Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pexelizumab · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| pexelizumab | DRUG | - |
INCLUSION CRITERIA: The study population will be drawn from patients undergoing CABG or CABG plus valve surgery using a bypass pump. In addition, they must meet all of the following criteria: * be at least 18 years of age; * have one or more of the following risk factors: * diabetes mellitus; * pr...
Pexelizumab is an investigational small molecule being studied for use in cardio-pulmonary bypass, specifically in patients undergoing coronary artery bypass graft surgery with cardio-pulmonary bypass. It is intended to address cardiovascular conditions related to this surgical procedure.
Pexelizumab is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical research on this investigational drug for cardiovascular applications.
Pexelizumab is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug is no longer in active clinical trials.
Pexelizumab was studied in a Phase 3 clinical trial with the identifier NCT00048308. This completed trial enrolled 3,000 participants and evaluated the effect of pexelizumab on all-cause mortality and myocardial infarction in patients undergoing coronary artery bypass graft surgery with cardio-pulmonary bypass.
No alternative names for pexelizumab have been disclosed. The drug is known by the single name pexelizumab in clinical research and development contexts.